Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHZD.L Regulatory News (HZD)

  • There is currently no data for HZD

Total Voting Rights

17 Feb 2020 07:00

RNS Number : 1351D
Horizon Discovery Group plc
17 February 2020
Β 

Β 

Β 

Β 

Horizon Discovery Group plc

Β 

Total Voting Rights

Β 

Β 

Cambridge, UK, 17 February 2020:Β In accordance with Disclosure and Transparency Rule 5.6.1 Horizon Discovery Group plc (the "Company") advises that:

Β 

As at 31 January 2020, the Company's issued share capital consisted of 150,692,631 ordinary shares of 1p each with voting rights. The Company does not hold any ordinary shares in Treasury.

Β 

The total number of voting rights in the Company is therefore 150,692,631.

Β 

The above figure (150,692,631) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Horizon Discovery Group plc under the FCA's Disclosure and Transparency Rules.

Β 

Β 

Ends

For further information from Horizon Discovery Group plc, please contact:

Horizon Discovery Group plc

Terry Pizzie, Chief Executive Officer

Jayesh Pankhania, Chief Financial Officer

Jon Davies, Head of Investor Relations

Tel: +44 (0) 1223 655 580

Β 

Numis Securities Limited (Broker and NOMAD)

Freddie Barnfield / Duncan Monteith

Tel: +44 (0) 207 260 1000

Β 

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott / Matthew Neal / Melissa Gardiner

Tel: +44 (0) 20 3709 5700

Email:Β horizon@consilium-comms.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
TVRGPUMPPUPUPGQ
Date   Source Headline
25th Mar 20157:00 amRNSHorizon Discovery awarded AMSCI grant
24th Mar 20157:00 amRNSNotice of Preliminary Results
23rd Mar 20157:00 amRNSHorizon Discovery and ArcherDX Sign OEM Agreement
18th Mar 201510:39 amRNSAdditional Listing
11th Mar 20157:00 amRNSHorizon Provides Genomic Standards To CRUK
18th Feb 20157:00 amRNSInnovate UK funding award
11th Feb 20154:27 pmRNSAdditional Listing
5th Feb 201512:21 pmRNSAdditional Listing
2nd Feb 20157:00 amRNSHorizon Discovery Selected as Core Facility
27th Jan 201512:00 pmRNSAdditional Listing
23rd Jan 20154:46 pmRNSHolding(s) in Company
19th Jan 20157:00 amRNSRevenues expected to be ahead of consensus by 7%
15th Jan 20157:00 amRNSHolding(s) in Company
8th Jan 20157:00 amRNSAcquisition of Haplogen Genomics GmbH
30th Dec 20147:00 amRNSHorizon Discovery Group Signs Agreement for $810K
22nd Dec 20144:49 pmRNSAdditional Listing
19th Dec 20146:23 pmRNSHolding(s) in Company
8th Dec 20147:00 amRNSLaunch of Gene-Engineered Bioproduction Cell Line
26th Nov 20143:09 pmRNSHolding(s) in Company
24th Nov 20147:00 amRNSHorizon Enter Agreement with Adarza BioSystems
19th Nov 201412:26 pmRNSHolding(s) in Company
17th Nov 20147:00 amRNS$750,000 contract win from top ten pharma
3rd Nov 20147:00 amRNSAppoints Dr David Smoller as an Executive Director
15th Oct 20147:00 amRNSHorizon CombinatoRx Wins Contract
6th Oct 20143:14 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
6th Oct 20147:00 amRNSCo-Exclusive Commercial Agreement Signed
29th Sep 20147:00 amRNSAcquires Sage Labs Inc. for $48M (£29M)
25th Sep 201412:30 pmRNSAdditional Listing
25th Sep 20147:00 amRNS$1.2 million Master Services Agreement
23rd Sep 20147:00 amRNSInterim Results for Six Months Ended 30 June 2014
17th Sep 20144:34 pmRNSHolding(s) in Company
15th Sep 20145:29 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
5th Sep 201410:17 amRNSAdditional Listing
3rd Sep 20147:00 amRNSNotice of Interim Results
5th Aug 20147:00 amRNSCRISPR Experts Join Scientific Advisory Board
28th Jul 20143:57 pmRNSAdditional Listing
25th Jul 20147:00 amRNSHZD sign Collaboration Agreement with Otsuka
23rd Jul 20147:00 amRNSTrading Update
3rd Jul 20147:00 amRNSLicenses AAV Gene Delivery Technology
19th Jun 201410:48 amRNSDirector/PDMR Shareholding
17th Jun 20143:35 pmRNSAdditional Listing
16th Jun 20147:00 amRNSTSB Grant for next generation cancer diagnostics
12th Jun 20147:00 amRNSLicenses CRISPR Technology from Broad Institute
11th Jun 201412:11 pmRNSDirector/PDMR Shareholding
9th Jun 20147:00 amRNSAppointment of two Non-Executive Directors
2nd Jun 20147:00 amRNSCompletion of Acquisition of CombinatoRx
15th May 20147:00 amRNSAcquisition
8th May 20147:00 amRNSHolding in Company
8th May 20147:00 amRNSLicenses Gene Editing Technology from ERS Genomics
6th May 20145:48 pmRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.